![Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/91b0943e-1019-4df5-8dc3-8dcc37d2b5ef/cam41422-toc-0001-m.jpg?trick=1689538360537)
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
![Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/Browse-tumor-types/heme/5mjc_ASH/4/Slide2.jpg)
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
![Study design and MRD time-points. RD: Lenalidomide-Dexamethasone, CTX:... | Download Scientific Diagram Study design and MRD time-points. RD: Lenalidomide-Dexamethasone, CTX:... | Download Scientific Diagram](https://www.researchgate.net/publication/309146023/figure/fig5/AS:417085126660099@1476452251741/Study-design-and-MRD-time-points-RD-Lenalidomide-Dexamethasone-CTX-Cyclophosphamide.png)
Study design and MRD time-points. RD: Lenalidomide-Dexamethasone, CTX:... | Download Scientific Diagram
![Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/027ea46a-9674-4627-be34-0c2a1eb0d7bf/gr1.gif)
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
![Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/Browse-tumor-types/heme/5mjc_ASH/1/Slide1.jpg)
Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
![Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/5/1/Slide03.jpg)
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
![Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S247395292031819X-absf1.jpg)
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
![Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/4054c0bb-6add-4d79-a311-e460cd3357f2/gr1.gif)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
![IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Pts: Results of the Spanish GEM2014MAIN Trial IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Pts: Results of the Spanish GEM2014MAIN Trial](https://i.ytimg.com/vi/aNmmCU7hEWs/maxresdefault.jpg)
IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Pts: Results of the Spanish GEM2014MAIN Trial
![PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c492928e3f0ff31a9045ef665d1d8113a4831731/3-Figure1-1.png)
PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar
![Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12185-019-02757-0/MediaObjects/12185_2019_2757_Fig1_HTML.png)
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
![Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile - Medwave Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile - Medwave](http://viejo.medwave.cl/medios/medwave/Mayo-Junio2018/7220/tb01_e7220.jpg)
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile - Medwave
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
![Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-021-00593-2/MediaObjects/41408_2021_593_Fig1_HTML.png)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
![Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma - Conquer: the journey informed Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma - Conquer: the journey informed](https://conquer-magazine.com/images/special_issues/2020/ASCO_Highlights/velcade_revlimid.jpg)